Ranibizumab antibody | AbD29928
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 (HCA304) at a concentration of 2 μg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate.
A microtiter plate was coated overnight with recombinant human VEGF-A (PHP293), ranibizumab or human Fab VH3-23/kappa1 at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, the human VEGF/ranibizumab complex was formed by adding 2 µg/ml ranibizumab to the wells coated with VEGF-A. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 (HCA304) titrated to the given concentrations and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with recombinant human VEGF-A (PHP293) at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 (HCA304) at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human anti Ranibizumab (Drug/Target Complex)
Anti-Ranibizumab Drug-Target Complex Antibody recognizes the ranibizumab/VEGF and bevacizumab/VEGF complexes exclusively, and is suitable for use in a PK antigen capture assay to detect these drugs and their biosimilars.
- Product Type
- Monoclonal Antibody
- Clone
- AbD29928
- Isotype
- HuCAL Fab monovalent
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA304 | E | 0.1 mg |
|
Human Anti-Ranibizumab Antibody, clone AbD29928 specifically recognizes the Fab fragment antibody drug ranibizumab when in complex with its target, human vascular endothelial growth factor A (VEGF-A). The antibody does not recognize free ranibizumab or unbound recombinant human VEGF-A. It can be used to measure levels of ranibizumab and biosimilars in patient samples.
Clone AbD29928 is a monovalent Fab format antibody that can be used to develop a pharmacokinetic (PK) antigen capture assay to measure free ranibizumab captured via immobilized VEGF-A.
This antibody also recognizes bevacizumab when in complex with human VEGF-A.
Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.
View a summary of all anti-ranibizumab antibodies
Clone AbD29928 is a monovalent Fab format antibody that can be used to develop a pharmacokinetic (PK) antigen capture assay to measure free ranibizumab captured via immobilized VEGF-A.
This antibody also recognizes bevacizumab when in complex with human VEGF-A.
Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.
View a summary of all anti-ranibizumab antibodies
Product Details
- Product Form
- A monovalent human recombinant Fab (kappa light chain) selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
- Preparation
- Metal chelate affinity chromatography
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Ranibizumab
- Affinity
- The monovalent intrinsic affinity of AbD29928 was measured as KD=1 nM by real time, label-free molecular interaction analysis on immobilized VEGF/ranibizumab complex.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Lucentis is a trademark of Genentech
His-tag is a trademark of EMD Biosciences. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Ranibizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- Clone AbD29928 is recommended for use as the detection reagent in an antigen capture assay to measure free ranibizumab captured via immobilized VEGF
Protocol: PK antigen capture ELISA to measure free drug
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Rat anti DYKDDDDK Tag:HRP | MCA4764P | E P WB | 0.1 mg |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml |
Product Specific References
References for Ranibizumab antibody
-
Harth, S. et al. (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
MAbs. 11 (1): 178-190.
